Lonza Group Ag (OTCMKTS:LZAGY) Sees Significant Increase in Short Interest

Lonza Group Ag (OTCMKTS:LZAGYGet Free Report) saw a significant growth in short interest in the month of April. As of April 30th, there was short interest totaling 27,348 shares, a growth of 117.6% from the April 15th total of 12,566 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 119,668 shares, the short-interest ratio is presently 0.2 days.

Analyst Ratings Changes

A number of research firms recently weighed in on LZAGY. Zacks Research upgraded Lonza Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. Royal Bank Of Canada raised shares of Lonza Group from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, February 11th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Check Out Our Latest Research Report on Lonza Group

Lonza Group Price Performance

OTCMKTS LZAGY opened at $59.51 on Friday. Lonza Group has a twelve month low of $58.53 and a twelve month high of $73.85. The company has a current ratio of 2.24, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. The firm’s 50 day moving average price is $63.07 and its two-hundred day moving average price is $66.30.

About Lonza Group

(Get Free Report)

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.

Featured Stories

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.